Payment overview · 2025
General Payments
$2,246.57
112 reported records · 22 companies
Healthcare provider profile · identity verified
John Rodgers, MD
Allopathic & Osteopathic Physicians|Internal Medicine · GLASTONBURY, CT · NPI 1588641112
Verified facts
What the public records show
CMS Open Payments records show John Rodgers, MD received $2,246.57 in general payments during 2025 across 112 reported records.
GlaxoSmithKline, LLC. accounted for 35.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 33 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Glassia, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BEVESPI AEROSPHERE as an associated drug or biological on 763 records involving 473 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Bevespi Aerosphere by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OFEV as an associated drug or biological on 14236 records involving 6873 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Ofev by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 450 claims for Trelegy Ellipta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Paxlovid by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GLASSIA as an associated drug or biological on 7881 records involving 3215 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Glassia by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $790.94 | 35.2% | 45 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $237.92 | 10.6% | 10 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $164.48 | 7.3% | 5 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $157.54 | 7.0% | 7 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $142.79 | 6.4% | 12 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $92.94 | 4.1% | 4 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $92.37 | 4.1% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $90.02 | 4.0% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $68.06 | 3.0% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $57.96 | 2.6% | 3 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $54.03 | 2.4% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $49.91 | 2.2% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $45.85 | 2.0% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $33.44 | 1.5% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $23.93 | 1.1% | 1 | 2025 |
| Valencia Technologies Corporation | Unresolved — no canonical attribution shown | $23.81 | 1.1% | 1 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $22.75 | 1.0% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $21.86 | 1.0% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.33 | 0.9% | 1 | 2025 |
| AbbVie Inc. | Unresolved — no canonical attribution shown | $18.87 | 0.8% | 1 | 2025 |
| IDORSIA PHARMACEUTICALS US INC | Unresolved — no canonical attribution shown | $18.81 | 0.8% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $17.96 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,246.57 | 112 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $593.69 | 29 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION | $164.48 | 5 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $157.54 | 7 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $123.36 | 6 | 2025 |
Source payment records
|
|||||
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $121.97 | 11 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $104.53 | 6 | 2025 |
Source payment records
|
|||||
| GLASSIA Normalized: glassia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $98.44 | 9 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $92.94 | 4 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $92.37 | 4 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $90.02 | 3 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $54.90 | 4 | 2025 |
Source payment records
|
|||||
| UNITHROID Normalized: unithroid |
Drug | Amneal Pharmaceuticals LLC | $54.03 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $50.73 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $49.91 | 2 | 2025 |
Source payment records
|
|||||
| FASENRA Normalized: fasenra |
Biological | AstraZeneca Pharmaceuticals LP | $45.86 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $45.85 | 2 | 2025 |
Source payment records
|
|||||
| CUVITRU Normalized: cuvitru |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $44.35 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $43.36 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $43.36 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $41.22 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $41.22 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $33.44 | 1 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $24.70 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $23.93 | 1 | 2025 |
Source payment records
|
|||||
| eCoin Device Kit Normalized: ecoin device kit |
Device | Valencia Technologies Corporation | $23.81 | 1 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $22.75 | 1 | 2025 |
Source payment records
|
|||||
| Brinsupri Normalized: brinsupri |
Drug | Insmed, Inc. | $22.75 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $21.86 | 1 | 2025 |
Source payment records
|
|||||
| JASCAYD Normalized: jascayd |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $20.33 | 1 | 2025 |
Source payment records
|
|||||
| EMBLAVEO Normalized: emblaveo |
Drug | AbbVie Inc. | $18.87 | 1 | 2025 |
Source payment records
|
|||||
| Quviviq Normalized: quviviq |
Drug | IDORSIA PHARMACEUTICALS US INC | $18.81 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $17.96 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $16.74 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| GLASSIA glassia |
2025 | Glassia | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 450 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BEVESPI AEROSPHERE open payments reported associated product |
CMS Open Payments — General Payments 763 supporting records · 473 recipient NPIs · example record 1206131384 |
Bevespi Aerosphere · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
48 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
49 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | OFEV open payments reported associated product |
CMS Open Payments — General Payments 14236 supporting records · 6873 recipient NPIs · example record 1221811762 |
Ofev · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
450 | 108 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
79 | 18 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
14 | 14 |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | GLASSIA open payments reported associated product |
CMS Open Payments — General Payments 7881 supporting records · 3215 recipient NPIs · example record 1223616286 |
Glassia · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 450 | 108 |
| Atorvastatin Calcium | Atorvastatin Calcium | 272 | 73 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 269 | 84 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 232 | 67 |
| Amlodipine Besylate | Amlodipine Besylate | 175 | 45 |
| Prednisone | Prednisone | 147 | 57 |
| Azithromycin | Azithromycin | 125 | 93 |
| Metoprolol Succinate | Metoprolol Succinate | 124 | 26 |
| Alprazolam | Alprazolam | 101 | 31 |
| Metoprolol Tartrate | Metoprolol Tartrate | 93 | 26 |
| Zolpidem Tartrate | Zolpidem Tartrate | 90 | 18 |
| Omeprazole | Omeprazole | 87 | 31 |
| Escitalopram Oxalate | Escitalopram Oxalate | 84 | 23 |
| Lisinopril | Lisinopril | 84 | 27 |
| Allopurinol | Allopurinol | 79 | 19 |
| Eliquis | Apixaban | 79 | 18 |
| Simvastatin | Simvastatin | 79 | 22 |
| Montelukast Sodium | Montelukast Sodium | 77 | 22 |
| Levothyroxine Sodium | Levothyroxine Sodium | 76 | 22 |
| Furosemide | Furosemide | 73 | 20 |
| Losartan Potassium | Losartan Potassium | 72 | 23 |
| Metformin Hcl | Metformin Hcl | 67 | 22 |
| Valsartan | Valsartan | 67 | 16 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 65 | 17 |
| Hydrochlorothiazide | Hydrochlorothiazide | 60 | 20 |
| Gabapentin | Gabapentin | 57 | 17 |
| Pantoprazole Sodium | Pantoprazole Sodium | 55 | 14 |
| Methylprednisolone | Methylprednisolone | 54 | 48 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 49 | 15 |
| Jardiance | Empagliflozin | 49 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 48 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 46 | 13 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 43 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 42 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 38 | suppressed |
| Xolair | Omalizumab | 35 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 34 | 17 |
| Breo Ellipta | Fluticasone/Vilanterol | 32 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 31 | 13 |
| Warfarin Sodium | Warfarin Sodium | 30 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 29 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 27 | 17 |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 27 | suppressed |
| Xarelto | Rivaroxaban | 26 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 24 | 21 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 24 | suppressed |
| Methocarbamol | Methocarbamol | 23 | suppressed |
| Ofev | Nintedanib Esylate | 23 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 23 | suppressed |
| Atenolol | Atenolol | 22 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 22 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 22 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 21 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 21 | suppressed |
| Mirtazapine | Mirtazapine | 21 | suppressed |
| Carvedilol | Carvedilol | 19 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 19 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 18 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 18 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 18 | suppressed |
| Ramipril | Ramipril | 18 | suppressed |
| Synthroid | Levothyroxine Sodium | 18 | suppressed |
| Ezetimibe | Ezetimibe | 17 | suppressed |
| Memantine Hcl | Memantine Hcl | 17 | suppressed |
| Vascepa | Icosapent Ethyl | 17 | suppressed |
| Azelastine-Fluticasone | Azelastine/Fluticasone | 16 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Lorazepam | Lorazepam | 16 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 15 | suppressed |
| Famotidine | Famotidine | 15 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 15 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 15 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Dulera | Mometasone/Formoterol | 14 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 14 | suppressed |
| Ibuprofen | Ibuprofen | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Testosterone | Testosterone | 14 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 13 | suppressed |
| Baclofen | Baclofen | 13 | suppressed |
| Carbamazepine | Carbamazepine | 13 | suppressed |
| Clotrimazole | Clotrimazole | 13 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 13 | suppressed |
| Finasteride | Finasteride | 13 | suppressed |
| Glassia | Alpha-1-Proteinase Inhibitor | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Lubiprostone | Lubiprostone | 13 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 13 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 13 | suppressed |
| Clonazepam | Clonazepam | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Potassium Chloride | Potassium Chloride | 12 | suppressed |
| Risperidone | Risperidone | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Bevespi Aerosphere | Glycopyrrolate/Formoterol Fum | 11 | suppressed |
| Cephalexin | Cephalexin | 11 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 11 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 11 | suppressed |
| Januvia | Sitagliptin Phosphate | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,246.57 · 112 records | GlaxoSmithKline, LLC. | AIRSUPRA, AREXVY, Arikayce, BREZTRI, Brinsupri, CAPLYTA, CUVITRU, Cologuard Collection Kit, DUPIXENT, EMBLAVEO, FASENRA, FREESTYLE LIBRE 3, GLASSIA, INSPIRE, JASCAYD, Kerendia, Leqembi, NUCALA, OTEZLA, Ohtuvayre, Ozempic, Quviviq, REPATHA, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, UNITHROID, UPLIZNA, VRAYLAR, VYNDAQEL, Wegovy, YUPELRI, eCoin Device Kit | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Glassia play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error